ATE452204T1 - Screening-methoden unter verwendung eines strukturmodells von fih - Google Patents

Screening-methoden unter verwendung eines strukturmodells von fih

Info

Publication number
ATE452204T1
ATE452204T1 AT03758318T AT03758318T ATE452204T1 AT E452204 T1 ATE452204 T1 AT E452204T1 AT 03758318 T AT03758318 T AT 03758318T AT 03758318 T AT03758318 T AT 03758318T AT E452204 T1 ATE452204 T1 AT E452204T1
Authority
AT
Austria
Prior art keywords
fih
structural model
structural
screening methods
chemical entity
Prior art date
Application number
AT03758318T
Other languages
English (en)
Inventor
Peter John Ratcliffe
Christopher William Pugh
Christopher Joseph Schofield
Kirsty Sarah Hewitson
Jonathan Mark Elkins
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224102A external-priority patent/GB0224102D0/en
Priority claimed from GB0226598A external-priority patent/GB0226598D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE452204T1 publication Critical patent/ATE452204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Computing Systems (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03758318T 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih ATE452204T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224102A GB0224102D0 (en) 2002-10-16 2002-10-16 Inhibitors
GB0226598A GB0226598D0 (en) 2002-11-14 2002-11-14 Chemical inhibitors
PCT/GB2003/004492 WO2004035812A2 (en) 2002-10-16 2003-10-16 Asparaginyl hydroxylases and modulators thereof

Publications (1)

Publication Number Publication Date
ATE452204T1 true ATE452204T1 (de) 2010-01-15

Family

ID=32109245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03758318T ATE452204T1 (de) 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih

Country Status (11)

Country Link
US (1) US7778779B2 (de)
EP (2) EP1554394B1 (de)
JP (1) JP4465276B2 (de)
AT (1) ATE452204T1 (de)
AU (1) AU2003274330B2 (de)
CA (1) CA2502541A1 (de)
DE (1) DE60330587D1 (de)
ES (1) ES2337043T3 (de)
MX (1) MXPA05004033A (de)
PL (1) PL376770A1 (de)
WO (1) WO2004035812A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638295B2 (en) 2004-03-26 2009-12-29 Isis Innovation Limited Assays for identifying modulators of the hydroxylation of ankyrin repeat proteins by 2-oxoglutarate dependent oxygenase and methods of using the same
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
GB0519605D0 (en) 2005-09-26 2005-11-02 Isis Innovation Assay
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
NZ623002A (en) 2006-06-26 2015-08-28 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2012512633A (ja) * 2008-12-19 2012-06-07 ヨーロピアン モレキュラー バイオロジー ラボラトリー エンドヌクレアーゼ活性を有するポリペプチド断片、及びそれらの使用
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
CN102595902B (zh) * 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
CA2774039A1 (en) 2009-11-06 2011-05-12 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (de) 2011-06-06 2018-03-17
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP3345596B1 (de) 2012-09-21 2021-01-20 Rhode Island Hospital Beta-hydrolase-hemmer zur behandlung von krebs
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
US10312653B2 (en) 2015-05-06 2019-06-04 Milwaukee Electric Tool Corporation Hydraulic tool
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
EP3582815A1 (de) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Verfahren zur behandlung von schizophrenie
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001251467A1 (en) 2000-05-17 2001-12-03 Princeton University Methods of making models, methods of using models of murg, compounds that bind, inhibit or stimulate muret proteins, and therapeutic compositions thereof
GB0017323D0 (en) 2000-07-15 2000-08-30 Univ St Andrews Enzyme
WO2002025276A1 (en) 2000-09-22 2002-03-28 Wyeth Crystal structure of bace and uses thereof
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
AUPR773801A0 (en) * 2001-09-18 2001-10-11 Adelaide Research & Innovation Pty Ltd Asparagine hydroxylation of the cad domain of a hif protein

Also Published As

Publication number Publication date
US7778779B2 (en) 2010-08-17
EP1554394A2 (de) 2005-07-20
MXPA05004033A (es) 2005-06-08
ES2337043T3 (es) 2010-04-20
DE60330587D1 (de) 2010-01-28
JP4465276B2 (ja) 2010-05-19
WO2004035812A2 (en) 2004-04-29
AU2003274330B2 (en) 2009-06-04
JP2006504415A (ja) 2006-02-09
AU2003274330A1 (en) 2004-05-04
US20070048728A1 (en) 2007-03-01
WO2004035812A3 (en) 2004-08-19
PL376770A1 (pl) 2006-01-09
EP2156830A1 (de) 2010-02-24
CA2502541A1 (en) 2004-04-29
EP1554394B1 (de) 2009-12-16

Similar Documents

Publication Publication Date Title
DE60330587D1 (de) Screening-Methoden unter Verwendung eines Strukturmodells von FIH
Livingstone et al. The prediction of hypolimnetic oxygen profiles: a plea for a deductive approach
Wisshak et al. Ocean acidification accelerates reef bioerosion
Burke et al. Evaluating and testing models of terrestrial biogeochemistry: the role of temperature in controlling decomposition
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
DE69735127D1 (de) Enzymsensor
DE602005027646D1 (de) Verfahren zum Betrieb eines Navigationssystems zum Melden aktualisierter Teile einer geographischen Datenbank
ATE496141T1 (de) Verfahren und system zum analysieren von reaktionen unter verwendung eines informationssystems
DE60334365D1 (de) Leistungsverbesserung einer analytenüberwachungsvorrichtung
EA200501193A1 (ru) Улучшенный способ и система для выявления и/или прогнозирования биологических аномалий, например церебральных нарушений
ATE507512T1 (de) Verfahren, computerprogramm mit programmcode- mitteln und computerprogramm-produkt zur analyse von einflussgrössen auf einen brennvorgang in einer brennkammer unter verwendung eines trainierbaren, statistischen modells
Liao et al. The comparison of the estimation of enzyme kinetic parameters by fitting reaction curve to the integrated Michaelis–Menten rate equations of different predictor variables
ATE221657T1 (de) Entstörung durch rheumafaktoren
Moyle et al. TP or not TP? Successful comparison of two independent methods validates total phosphorus inference for long-term eutrophication studies
DE69928250D1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
Lu et al. Multivariate calibration models based on the direct analysis of near-infrared single-beam spectra
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
ATE185377T1 (de) Genomische genkartierungsmethode durch direkten nachweis von haplotypen mittels intronsequenzanalyse
DE602005019578D1 (de) Verfahren und vorrichtung zur bestimmung der aufzeichnungsparameter von optischen platten
DE3850346D1 (de) Verfahren zur Selbstdurchführung von Enzymkinetik.
ATE527596T1 (de) Erhalten von konfigurationsdaten für ein datenverarbeitungsgerät
DE602005015627D1 (de) Verfahren zur messung von proinsulin und c-peptid sowie kit dafür
Boushaba et al. Dynamics of the ‘echo’effect in a phytoplankton system with nitrogen fixation
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties